Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/irv.12171 http://scihub22266oqcxt.onion/10.1111/irv.12171 24215382!6492653!24215382     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Influenza+Other+Respir+Viruses 2013 ; 7 Suppl 3 (Suppl 3): 52-9 Nephropedia Template TP {{tp|p=24215382|t=2013. Adjunctive therapies and immunomodulating agents for severe influenza |pdf=|usr=}}{{24215382}} gab.com Text Adjunctive therapies and immunomodulating agents for severe influenza JO: Influenza Other Respir Viruses http://www.kidney.de/pget.php?&tw=1&pmid=24215382 #FOAvip The value of adjunctive immunomodulatory therapies in treating severe influenza and other respiratory viral infections remains uncertain. Although often used, systemic corticosteroids may increase the risk of mortality and morbidity (e.g. secondary infections) in severe influenza and other viral infections, especially if there is delay or lack of effective antiviral therapy. Non-randomized studies suggest that convalescent plasma appears useful as add-on therapy for patients with severe acute respiratory syndrome, avian influenza A(H5N1), and influenza A (H1N1) 2009 pandemic [A(H1N1)pdm09), but it is limited by its availability. A recent randomized controlled trial (RCT) comparing hyperimmune globulin prepared from convalescent plasma against normal intravenous gammaglobulin (IVIG) manufactured before 2009 as control in patients with severe A(H1N1)pdm09 infection on standard antiviral treatment has shown that the hyperimmune globulin group who received treatment within 5 days of symptom onset had a lower viral load and reduced mortality compared with the controls. A number of agents with immunomodulatory effects (e.g. acute use of statins, N-acetylcysteine, macrolides, PPAR agonists, IVIG, celecoxib, mesalazine) have been proposed for influenza management. However, more animal and detailed human observational studies and preferably RCTs controlling for the effects of antiviral therapy and disease severity are needed for evaluating these agents. The role of plasmapheresis and hemoperfusion as rescue therapy also merits more investigation. Twit Text FOAVip Adjunctive therapies and immunomodulating agents for severe influenza ????Influenza Other Respir Viruses http://www.kidney.de/pget.php?&tw=1&pmid=24215382 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24215382 #FOAvip English Wikipedia <ref>{{Cite pmid|24215382}}</ref> Adjunctive therapies and immunomodulating agents for severe influenza #MMPMID24215382 Hui DS; Lee N Influenza Other Respir Viruses 2013[Nov]; 7 Suppl 3 (Suppl 3): 52-9 PMID24215382show ga The value of adjunctive immunomodulatory therapies in treating severe influenza and other respiratory viral infections remains uncertain. Although often used, systemic corticosteroids may increase the risk of mortality and morbidity (e.g. secondary infections) in severe influenza and other viral infections, especially if there is delay or lack of effective antiviral therapy. Non-randomized studies suggest that convalescent plasma appears useful as add-on therapy for patients with severe acute respiratory syndrome, avian influenza A(H5N1), and influenza A (H1N1) 2009 pandemic [A(H1N1)pdm09), but it is limited by its availability. A recent randomized controlled trial (RCT) comparing hyperimmune globulin prepared from convalescent plasma against normal intravenous gammaglobulin (IVIG) manufactured before 2009 as control in patients with severe A(H1N1)pdm09 infection on standard antiviral treatment has shown that the hyperimmune globulin group who received treatment within 5 days of symptom onset had a lower viral load and reduced mortality compared with the controls. A number of agents with immunomodulatory effects (e.g. acute use of statins, N-acetylcysteine, macrolides, PPAR agonists, IVIG, celecoxib, mesalazine) have been proposed for influenza management. However, more animal and detailed human observational studies and preferably RCTs controlling for the effects of antiviral therapy and disease severity are needed for evaluating these agents. The role of plasmapheresis and hemoperfusion as rescue therapy also merits more investigation. |*Immunomodulation[MESH] |Animals[MESH] |Humans[MESH] |Immunologic Factors/*therapeutic use[MESH] |Influenza A Virus, H1N1 Subtype/physiology[MESH] |Influenza A Virus, H5N1 Subtype/physiology[MESH] |Influenza, Human/*immunology/*therapy/virology[MESH]Adjunctive therapies and immunomodulating agents for severe influenza (epmc).pdf DeepDyve Pubget Overpricing